Status:
COMPLETED
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections
Lead Sponsor:
Tourcoing Hospital
Conditions:
Prosthesis-related Infections
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this retrospective observational study is to evaluate the efficacy of antibiotic therapy with dalbavancin in patients presenting with infection on prosthetic devices. The main questions the...
Eligibility Criteria
Inclusion
- Patients with inextricable and/or inoperable osteoarticular or vascular prosthetic material.
- Patients requiring suppressive antibiotic therapy (\>6 months) with dalbavancin.
Exclusion
- Patients who are protected adult;
- Patients who are minors;
- Patients having expressed their opposition
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06089044
Start Date
January 1 2020
End Date
December 31 2022
Last Update
October 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Tourcoing
Tourcoing, France